Curanex Pharmaceuticals Inc (CURX)

$0.31 +0.00 (0.76%)
Market Cap 8.60M
Revenue (ttm) 0.00
Net Income (ttm) -4.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 52,600
Avg Vol 106,990
Day's Range N/A - N/A
Shares Out 28.37M
Stochastic %K 8%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals I...

Industry: Biotechnology
Sector: Healthcare
Phone: 718 673 6078
Address:
2 Jericho Plaza, Suite 101B, Jericho, United States
OnlyFibs
OnlyFibs May. 24 at 8:12 PM
Total consolidated quarterly revenues for $CURX show stabilization as product mix optimization drives structural margin improvement. This highly predictable biotech cash engine completely backstops the lower boundaries of the chart, giving active swing traders an exceptionally clean, data-driven risk-reward layout right against the immediate range floor. 🎯 Levels to Confirm: 🐂 Bulls: Clear $0.35 on an 8-hour close for $CURX to step past the broken floor resistance and open a wide runway to $0.44. 🐻 Bears: $CURX must break through the final horizontal defense layer at $0.31 to maintain absolute downside control for a deep flush. #GrowthStocks #EarningsPower #ValueInvesting #StockMarket #hovdid
0 · Reply
Russiancolusion
Russiancolusion May. 20 at 9:41 AM
$CURX oh ya update. Used to think this company was a scam. Now think just didn't have enough to $$ fór sales people and PR
0 · Reply
Russiancolusion
Russiancolusion May. 20 at 9:39 AM
$CURX $CURX SHOULD BE ABOVE $1.00 BY NOVEMBER before being forced to reverse split because a unamed Giant with the letters J&J in the name are interested in putting in there creams "Allegedly" to help treat skin conditions.....wink wink say no more say no more. Jump on this when I see big buys and buy over .75 cents then God knows where it goes. Not going to bet the house but seems logical if it has skin benefits and a Giant buys shares or just buys 49% of the company could go back to IPO prices plus 50% short term. Short meaning early 2027... Following buying some now and easing in to .75 then all in x12
0 · Reply
Brokechump
Brokechump May. 14 at 1:05 PM
$CURX News out.
0 · Reply
Russiancolusion
Russiancolusion May. 12 at 5:04 PM
$CURX How do these scam companies get listed ?
0 · Reply
Brokechump
Brokechump May. 7 at 3:56 PM
$CURX Will they ask for the extension or just execute RS
1 · Reply
Brokechump
Brokechump May. 5 at 8:30 PM
$CURX What happened. We were doing so well. Dammit
0 · Reply
SkullInferno
SkullInferno May. 1 at 11:43 PM
$CURX dilution risk
0 · Reply
Brokechump
Brokechump Apr. 21 at 9:55 PM
$CURX This is stagnet remote pond water movement . Damn.
0 · Reply
Brokechump
Brokechump Apr. 21 at 12:09 AM
$CURX can we be going up?
0 · Reply
Latest News on CURX
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

May 14, 2026, 8:53 AM EDT - 25 days ago

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Apr 8, 2026, 7:47 AM EDT - 2 months ago

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Curanex highlights patient case study in treatment of cancer cachexia

2026-04-06T13:58:25.000Z - 2 months ago

Curanex highlights patient case study in treatment of cancer cachexia

Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care

Apr 6, 2026, 9:17 AM EDT - 2 months ago

Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care

Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development Company

Apr 2, 2026, 8:07 AM EDT - 2 months ago

Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development Company

Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission

Mar 30, 2026, 5:35 PM EDT - 2 months ago

Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission

Curanex completes dose-range finding toxicology study of Phyto-N

2026-03-18T12:17:58.000Z - 2 months ago

Curanex completes dose-range finding toxicology study of Phyto-N

Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission

Mar 18, 2026, 8:00 AM EDT - 2 months ago

Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission

Curanex Expands Scientific Advisory Board With Two Distinguished Researchers

Mar 12, 2026, 9:30 AM EDT - 3 months ago

Curanex Expands Scientific Advisory Board With Two Distinguished Researchers

Curanex appoints two research experts to board of directors

2026-03-11T12:23:14.000Z - 3 months ago

Curanex appoints two research experts to board of directors

BMY

Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board

Mar 11, 2026, 8:00 AM EDT - 3 months ago

Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board

Curanex announces formation of Scientific Advisory Board

2026-03-05T13:25:48.000Z - 3 months ago

Curanex announces formation of Scientific Advisory Board

Curanex Forms World Class Scientific Advisory Board

Mar 5, 2026, 8:00 AM EST - 3 months ago

Curanex Forms World Class Scientific Advisory Board

Curanex provides operational update on regulatory milestones

2026-02-25T13:17:16.000Z - 3 months ago

Curanex provides operational update on regulatory milestones

Curanex Provides Operational Update on Key Regulatory Milestones

Feb 25, 2026, 8:00 AM EST - 3 months ago

Curanex Provides Operational Update on Key Regulatory Milestones

Curanex engages Strategic Investor Relations to enhance Curanex’s visibility

2025-10-22T11:15:34.000Z - 8 months ago

Curanex engages Strategic Investor Relations to enhance Curanex’s visibility

Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement

Oct 22, 2025, 7:00 AM EDT - 8 months ago

Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement

Curanex Pharmaceuticals Inc trading resumes

2025-09-17T15:35:16.000Z - 9 months ago

Curanex Pharmaceuticals Inc trading resumes

Curanex Pharmaceuticals Inc trading halted, volatility trading pause

2025-09-17T15:20:18.000Z - 9 months ago

Curanex Pharmaceuticals Inc trading halted, volatility trading pause

Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters

Sep 12, 2025, 2:46 PM EDT - 9 months ago

Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters

Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering

Aug 27, 2025, 5:00 PM EDT - 10 months ago

Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering

Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering

Aug 26, 2025, 7:30 AM EDT - 10 months ago

Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering

Preclinical biopharma Curanex Pharmaceuticals files for a $10 million IPO

Oct 16, 2024, 7:01 PM EDT - 1 year ago

Preclinical biopharma Curanex Pharmaceuticals files for a $10 million IPO

Curanex Pharmaceuticals IPO Registration Document (S-1)

Oct 16, 2024, 5:29 PM EDT - 1 year ago

Curanex Pharmaceuticals IPO Registration Document (S-1)

OnlyFibs
OnlyFibs May. 24 at 8:12 PM
Total consolidated quarterly revenues for $CURX show stabilization as product mix optimization drives structural margin improvement. This highly predictable biotech cash engine completely backstops the lower boundaries of the chart, giving active swing traders an exceptionally clean, data-driven risk-reward layout right against the immediate range floor. 🎯 Levels to Confirm: 🐂 Bulls: Clear $0.35 on an 8-hour close for $CURX to step past the broken floor resistance and open a wide runway to $0.44. 🐻 Bears: $CURX must break through the final horizontal defense layer at $0.31 to maintain absolute downside control for a deep flush. #GrowthStocks #EarningsPower #ValueInvesting #StockMarket #hovdid
0 · Reply
Russiancolusion
Russiancolusion May. 20 at 9:41 AM
$CURX oh ya update. Used to think this company was a scam. Now think just didn't have enough to $$ fór sales people and PR
0 · Reply
Russiancolusion
Russiancolusion May. 20 at 9:39 AM
$CURX $CURX SHOULD BE ABOVE $1.00 BY NOVEMBER before being forced to reverse split because a unamed Giant with the letters J&J in the name are interested in putting in there creams "Allegedly" to help treat skin conditions.....wink wink say no more say no more. Jump on this when I see big buys and buy over .75 cents then God knows where it goes. Not going to bet the house but seems logical if it has skin benefits and a Giant buys shares or just buys 49% of the company could go back to IPO prices plus 50% short term. Short meaning early 2027... Following buying some now and easing in to .75 then all in x12
0 · Reply
Brokechump
Brokechump May. 14 at 1:05 PM
$CURX News out.
0 · Reply
Russiancolusion
Russiancolusion May. 12 at 5:04 PM
$CURX How do these scam companies get listed ?
0 · Reply
Brokechump
Brokechump May. 7 at 3:56 PM
$CURX Will they ask for the extension or just execute RS
1 · Reply
Brokechump
Brokechump May. 5 at 8:30 PM
$CURX What happened. We were doing so well. Dammit
0 · Reply
SkullInferno
SkullInferno May. 1 at 11:43 PM
$CURX dilution risk
0 · Reply
Brokechump
Brokechump Apr. 21 at 9:55 PM
$CURX This is stagnet remote pond water movement . Damn.
0 · Reply
Brokechump
Brokechump Apr. 21 at 12:09 AM
$CURX can we be going up?
0 · Reply
focafoca99
focafoca99 Apr. 8 at 7:58 PM
$CURX highlighted five additional patient cases that it says further support the potential of its lead candidate in cancer cachexia and severe systemic decline.
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 8 at 11:47 AM
$CURX Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline
0 · Reply
Russiancolusion
Russiancolusion Apr. 7 at 8:59 PM
$CURX someone is getting rich. Puty deposit on a new Lotus. Buy the dip Dip
0 · Reply
MoxeysPal
MoxeysPal Apr. 6 at 10:01 PM
$CURX you need to start trading this s*** stock . Buy 46 sell it 53 rinse and repeat over and over, buck it
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 6 at 7:28 PM
$AIXI Boombayah 362%!!! Keep an eye on $CURX another penny today
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 6 at 2:24 PM
$CURX Cat Bounce Set Up Used to be $9.18 now $0.53 (94% Drop) . Market is on Fire today for Trading $SMX $FCUV $PFSA $MAXN
1 · Reply
Stock_Catcher
Stock_Catcher Apr. 6 at 2:02 PM
$CURX only up 3% super thin stock, daily break out over 0.50 psych level. Had Positive Cancer News This Morning . Thin stocks ripping is theme today 50%+ $MAXN $FCUV $MLEC $CREG
1 · Reply
Stock_Catcher
Stock_Catcher Apr. 6 at 1:17 PM
$CURX Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 2 at 12:07 PM
$CURX Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company
0 · Reply
The_Sophisticate
The_Sophisticate Mar. 31 at 5:31 PM
$CURX get in
0 · Reply
realcon
realcon Mar. 31 at 2:36 PM
$CURX all in after LTRN profits
0 · Reply
focafoca99
focafoca99 Mar. 31 at 1:51 AM
$CURX is still early, but this update at least shows Phyto-N moving toward a planned Q4 2026 IND with manufacturing, tox and patent work all moving in parallel.
0 · Reply